✦ LIBER ✦

Multiple biologic markers in the monitoring of treatment for patients with small cell carcinoma of the lung: The use of serial levels of plasma cea and serum carbohydrates

✍ Scribed by Kwang B. Woo; T. Waalkes Phillip Phd; Martin D. Abeloff; David S. Ettinger; Karen L. McNitt; Charles W. Gehrke

Publisher: John Wiley and Sons
Year: 1981
Tongue: English
Weight: 874 KB
Volume: 48
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19811001)48:7<1633::aid-cncr2820480727>3.0.co;2-d

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The use and limitations of serial plasma

The use and limitations of serial plasma carcinoembryonic antigen (CEA) levels as a monitor of changing metastatic liver tumor volume in patients receiving chemotherapy

✍ B. R. Bronstein; G. D. Steele Jr.; W. Ensminger; W. D. Kaplan; M. S. Lowenstein; 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 506 KB

Metallothionein expression in patients w

Metallothionein expression in patients with small cell carcinoma of the lung : Correlation with other molecular markers and clinical outcome

✍ Mariamma G. Joseph; Diponkar Banerjee; Walter Kocha; Ronald Feld; Larry W. Stitt 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 227 KB 👁 3 views

The addition of cisplatin to cyclophosph

The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma : A randomized study of 457 patients

✍ Thierry Urban; Claude Chastang; François-Xavier Lebas; Jean-Paul Duhamel; Guy Ad 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

## BACKGROUND. To assess whether the addition of cisplatin (100 mg/m 2 administered intravenously on Day 1) to CDE (cyclophosphamide [1000 mg/m 2 on Day 1], doxorubicin [45 mg/m 2 on Day 1], and etoposide [150 mg/m 2 on Days 1 and 2] combination is useful in the treatment of patients with small cel

Weekly alternating therapy with irinotec

Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma

✍ William N. William Jr; James Uyeki; Faye M. Johnson; Lei Feng; Beverly O. Peeple 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 171 KB 👁 1 views

Paclitaxel, carboplatin, and topotecan i

Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung carcinoma : A Phase II trial of the Minnie Pearl Cancer Research Network

✍ John D. Hainsworth; Lisa H. Morrissey; Daniel C. Scullin Jr.; Gerry Ann Houston; 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 2 views

## Abstract ## BACKGROUND The objective of this study was to evaluate the feasibility, toxicity, and efficacy of a novel three‐drug regimen containing paclitaxel, carboplatin, and topotecan followed by oral etoposide in the first‐line treatment of patients with small cell lung carcinoma. ## METHO

Pretreatment fibrinogen levels are assoc

Pretreatment fibrinogen levels are associated with response to chemotherapy in patients with small cell carcinoma of the lung: Department of veterans affairs cooperative study 188

✍ Kenneth R. Meehan; Leo R. Zacharski; Thomas E. Moritz; Frederick R. Rickles 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 608 KB